Zai Lab (ZLAB) said Wednesday that data from the China subpopulation of a global phase 3 trial showed an improved overall survival after treatment with Tivdak in patients with recurrent or metastatic cervical cancer compared with chemotherapy.
The company said the China results were consistent with those seen in the global population as the drug candidate showed a 45% decrease in the risk of death compared with chemotherapy.
Main secondary endpoints of progression-free survival and objective response rate also "favored treatment with Tivdak compared to chemotherapy," Zai Lab said.
The company said it plans to file a new drug application with China's National Medical Products Administration in Q1.
ZLAB shares were up 2.8% in early trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。